{
    "biomarker_id": "BB3882-1",
    "biomarker_canonical_id": "BB3882",
    "condition": {
        "recommended_name": {
            "id": "DOID:0060224",
            "resource": "Disease Ontology",
            "url": "https://disease-ontology.org/term/DOID:0060224",
            "name": "atrial fibrillation",
            "description": "A heart conduction disease that is characterized by uncoordinated electrical activity in the heart's upper chambers (the atria), which causes the heartbeat to become fast and irregular and has symptoms palpitations, weakness, fatigue, lightheadedness, dizziness, confusion, shortness of breath and chest pain."
        },
        "synonyms": [
            {
                "id": "DOID:0060224",
                "resource": "Disease Ontology",
                "url": "https://disease-ontology.org/term/DOID:0060224",
                "name": "A-fib",
                "description": ""
            },
            {
                "id": "DOID:0060224",
                "resource": "Disease Ontology",
                "url": "https://disease-ontology.org/term/DOID:0060224",
                "name": "AFib",
                "description": ""
            }
        ],
        "id": "DOID:0060224"
    },
    "biomarker_component": [
        {
            "biomarker": "increased level of N4H5 on fibrinogen",
            "assessed_biomarker_entity_id": "P02671-1",
            "assessed_entity_type": "protein",
            "assessed_biomarker_entity": {
                "recommended_name": "Fibrinogen alpha chain",
                "synonyms": []
            },
            "specimen": [
                {
                    "name": "blood plasma",
                    "namespace": "UBERON",
                    "id": "0001969",
                    "url": "http://purl.obolibrary.org/obo/UBERON_0001969",
                    "loinc_code": ""
                }
            ],
            "evidence_source": [
                {
                    "id": "BB3882-1",
                    "database": "BiomarkerKB",
                    "url": "https://biomarkerkb.org/biomarker/BB3882-1"
                },
                {
                    "id": "40099449",
                    "database": "PubMed",
                    "url": "",
                    "tags": [
                        "assessed_biomarker_entity_id",
                        " assessed_biomarker_entiy",
                        " assessed_entity_type",
                        " biomarker",
                        " specimen"
                    ],
                    "evidence_list": [
                        {
                            "evidence": "Application to 181 atrial fibrillation (AF) patients and 52 healthy controls identified three gamma chain glycoforms significantly associated with AF. Most notably, increased levels of the asialylated N4H5, known to enhance fibrin bundle thickness and promote clot formation, suggest a potential mechanism linking glycosylation changes to the prothrombotic state in AF. Regression analysis identified three glycopeptides significantly associated with AF, all of which were lower-abundance glycopeptides from the Gamma glycosylation site (Table 3). Specifically, Gamma. MISS-N4H5, Gamma. MISS-N4H5S1F1, and Gamma. MISS-N4H5S2F1 were found to be more abundant in AF patients compared to the controls. The most notable finding was an increase in the level of Gamma. MISS-N4H5, an asialylated glycoform. Asialylated fibrinogen is known to enhance clot formation, producing fibrin bundles with greater thickness compared to those formed by fibrinogen with disialylated glycans. 24 Given that AF patients are predisposed to clot formation and routinely prescribed anticoagulants,46 these glycosylation changes could have functional implications in the prothrombotic state associated with AF. Notably, an increase in the asialylated glycoform Gamma. MISS-N4H5 was observed in AF patients, which may contribute to the prothrombotic state seen under this condition."
                        }
                    ]
                }
            ]
        }
    ],
    "best_biomarker_role": [
        {
            "role": ""
        }
    ],
    "evidence_source": [
        {
            "id": "BB3882-1",
            "database": "BiomarkerKB",
            "url": "https://biomarkerkb.org/biomarker/BB3882-1"
        },
        {
            "id": "40099449",
            "database": "PubMed",
            "url": "",
            "tags": [
                "condition"
            ],
            "evidence_list": [
                {
                    "evidence": "Application to 181 atrial fibrillation (AF) patients and 52 healthy controls identified three gamma chain glycoforms significantly associated with AF. Most notably, increased levels of the asialylated N4H5, known to enhance fibrin bundle thickness and promote clot formation, suggest a potential mechanism linking glycosylation changes to the prothrombotic state in AF. Regression analysis identified three glycopeptides significantly associated with AF, all of which were lower-abundance glycopeptides from the Gamma glycosylation site (Table 3). Specifically, Gamma. MISS-N4H5, Gamma. MISS-N4H5S1F1, and Gamma. MISS-N4H5S2F1 were found to be more abundant in AF patients compared to the controls. The most notable finding was an increase in the level of Gamma. MISS-N4H5, an asialylated glycoform. Asialylated fibrinogen is known to enhance clot formation, producing fibrin bundles with greater thickness compared to those formed by fibrinogen with disialylated glycans. 24 Given that AF patients are predisposed to clot formation and routinely prescribed anticoagulants,46 these glycosylation changes could have functional implications in the prothrombotic state associated with AF. Notably, an increase in the asialylated glycoform Gamma. MISS-N4H5 was observed in AF patients, which may contribute to the prothrombotic state seen under this condition."
                }
            ]
        }
    ],
    "crossref": [
        {
            "id": "BB3882-1",
            "database": "BiomarkerKB",
            "url": "https://biomarkerkb.org/biomarker/BB3882-1",
            "categories": [
                "Biomarkers"
            ]
        }
    ],
    "citation": [],
    "section_stats": [
        {
            "table_id": "biomarker_component",
            "table_stats": [
                {
                    "field": "total",
                    "count": 1
                }
            ],
            "sort_fields": [
                "biomarker",
                "assessed_biomarker_entity_id",
                "assessed_entity_type",
                "assessed_biomarker_entity.recommended_name"
            ]
        },
        {
            "table_id": "citation",
            "table_stats": [
                {
                    "field": "total",
                    "count": 0
                }
            ],
            "sort_fields": []
        }
    ]
}